Merck KGaA Sells Théramex To Teva for EUR 265 million
- Details
- Category: Merck Group
Merck KGaA announced that it will sell Théramex, its Monaco-based pharmaceutical company specialized in women's health and gynecology, to Teva. Merck and Teva have signed an agreement whereby Teva will acquire all Théramex operations including 100% of the shares of Théramex S.A.M of Monaco and Théramex S.p.A. of Italy for a consideration of EUR 265 million.
Bayer lifts sales and earnings again
- Details
- Category: Bayer
Sales of the Bayer Group rose by 16.1 percent in the third quarter, to EUR 8,581 million (Q3 2009: EUR 7,392 million). Adjusted for currency and portfolio effects, business expanded by 8.4 percent. Earnings before interest, taxes, depreciation and amortization (EBITDA) - before special items - improved by 10.5 percent to EUR 1,656 million (Q3 2009: EUR 1,499 million).
Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment.
Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth.
Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million
- Details
- Category: Merck Group
Merck Group third-quarter total revenues increased 25% to a record EUR 2,438 million from EUR 1,950 million in the year-ago quarter, boosted by the EUR 5.1 billion acquisition of Millipore Corporation, Billerica, Massachusetts, USA, on July 14.
AstraZeneca initiates phase IIB study for AZD9773
- Details
- Category: AstraZeneca
AstraZeneca has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sepsis and/or septic shock receiving best supportive care. The Phase IIb study is a multicentre, randomised, double-blind, placebo controlled trial in 300 patients which will evaluate the efficacy of two intravenous dosing regimens of AZD9773.
FDA approves Herceptin for HER2-positive metastatic stomach cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.
More Pharma News ...
- Novartis delivers excellent performance in third quarter
- US FDA Approves Pradaxa® (dabigatran etexilate)
- Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
- Genzyme Reports Financial Results for the Third Quarter of 2010
- Genzyme Announces Results of Phase 3 Trial of Clolar
- Sanofi-aventis Establishes Research Collaboration with Harvard University
- Biocon and Pfizer Enter Into Global Commercialization Agreement